Traynor Capital Management, Inc. Nektar Therapeutics Transaction History

Traynor Capital Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 01, 2019	SELL	$16.91 - $36.27 $596,077 - $1.28 Million	-35,250 Closed	0 $0
Q2 2019 Jul 26, 2019	BUY	$31.0 - $36.3 $874,975 - $1.02 Million	28,225 Added 401.78%	35,250 $1.26 Million
Q1 2019 Apr 12, 2019	BUY	$31.58 - $46.35 $221,849 - $325,608	7,025 New	7,025 $236,000

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Traynor Capital Management, Inc. with notifications on news.